Results 211 to 220 of about 6,389 (282)

The Dynamic Evolution of Lipid Profiles Following Transjugular Intrahepatic Portosystemic Shunt in Patients With Liver Cirrhosis

Portal Hypertension &Cirrhosis, EarlyView.
Cirrhosis is frequently accompanied by varying degrees of lipid profile abnormalities. This study confirms that these profiles are differentially affected by disease etiology and progressively worsen—with significant reductions in TC, HDL‐C, and LDL‐C—as liver disease severity increases. TIPS improves lipid profiles, particularly by increasing HDL‐C in
Jiamin Xu, Qinnian Li, Lagan Kumar Manandhar, Bilian Zhu, Chenrui Zhang, Weimin Bao, Yingmei Tang   +6 more
wiley   +1 more source

Effects of Intravenous Laser Irradiation of Blood on Metabolic Markers in Patients With Hyperlipidemia: A Retrospective Pilot Study. [PDF]

In Vivo
Huang CY, Lee CY, Chiang IT, Chang Y, Kung LC, Chen WT, Chang HF, Su LT, Lan TM, Chiu PE, Liu YC.   +10 more
europepmc   +1 more source

Uric Acid in Metabolic Dysfunction‐Associated Steatotic Liver Disease

Portal Hypertension &Cirrhosis, EarlyView.
MASLD is the most prevalent chronic liver disease worldwide, yet effective pharmacological treatments remain limited. Hyperuricemia is now recognized as a key driver of hepatic steatosis, inflammation, and fibrosis, with elevated serum uric acid levels independently predicting hepatocellular carcinoma and liver‐related mortality.
Rong Wang, Zhenyu Liu, Jun Lin, Weijing Zhang, Xianzhi Liu, Tong Zhang   +5 more
wiley   +1 more source

Pharmacogenomics-based systematic review of coronary artery disease based on personalized medicine procedure. [PDF]

Heliyon
Kazemi Asl S, Rahimzadegan M, Kazemi Asl A.   +2 more
europepmc   +1 more source

Harnessing Natural Compounds in Psoriasis: Targeting Cellular Pathways for Effective Therapy

Phytotherapy Research, EarlyView.
Natural compounds act on key cellular pathways in psoriasis by suppressing keratinocyte hyperproliferation, modulating Th17/IL‐17‐mediated immune responses, and reducing oxidative stress. These multi‐target effects highlight their potential as safer adjunctive therapies alongside conventional treatments.
Hye Jin Lee, Yu Jin So, Il‐Joo Jo, Ji Yong Jang, Tae Han Yook, Jun Ho Lee, Sung Wook Kim, Kangwook Lee, Soo Jung Park, Gabsik Yang   +9 more
wiley   +1 more source

Ultrasound measurements of croup fat thickness and liver echogenicity as indicators for lipomobilization in donkeys (Equus Africanus asinus) with fasting-induced hyperlipidemia. [PDF]

BMC Vet Res
Mahmoud AAE, Elsayed HK, Hussein HA.
europepmc   +1 more source

Hederagenin Attenuates Cardiac Remodeling by Targeting Phosphodiesterase 9A

Phytotherapy Research, EarlyView.
ABSTRACT Background and Aim New therapeutic strategies for heart failure are urgently needed. The protective effects of cyclic guanosine monophosphate (cGMP)—protein kinase G (PKG) pathway on heart have been widely reported. Despite phosphodiesterase 9A (PDE9A) inhibitors combating cardiac remodeling, clinically available drugs are lacking. Hederagenin
Liqian Chen, Xinghong Zhou, Yanting You, Jieyu Chen, Baizhao Peng, Yijian Deng, Shuai Ji, Ying Yang, Xiaohu Chen, Huaxi Liu, Shuxuan Yang, Hiu Yee Kwan, Wen Jin, Lei Zhang, Yuegang Wang, Xiaoshan Zhao, Yanyan Liu   +16 more
wiley   +1 more source

Comparative Effectiveness of Cholesteryl Ester Transfer Protein (CETP) Inhibitors on Lipid Profiles in Adults With Hyperlipidemia: A Comprehensive Systematic Review and Frequentist Network Meta-Analysis of Randomized Controlled Trials. [PDF]

Clin Cardiol
Khalil I, Islam MR, Promi SA, Joy AD, Sayed MA, Acharjee D, Al-Shammari AS, Abrar S, Jamil TB, Taseen M, Biswas S, Mifty SK, Al-Badri SG, Debnath A, Hossain MI, Akter M.   +15 more
europepmc   +1 more source

Hepatic fibrosis in patients diagnosed with rheumatoid arthritis and psoriatic arthritis receiving methotrexate: A cross‐sectional analysis using transient elastography

Rheumatology &Autoimmunity, EarlyView.
Hepatic fibrosis and metabolic syndrome are more prevalent in PsA patients treated with methotrexate, compared to RA patients. Metabolic syndrome is associated with the risk of hepatic fibrosis in patients diagnosed with PsA and RA even after adjustment forcumulative methotrexate exposure.
Ratchaya Lertnawapan, Soonthorn Chonprasertsuk, Sith Siramolpiwat, Kanon Jatuworapruk   +3 more
wiley   +1 more source